AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 103 filers reported holding AKERO THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 4.79 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,580,240 | +25.3% | 70,784 | +15.7% | 0.00% | +33.3% |
| Q2 2023 | $2,856,214 | +135975.0% | 61,174 | +11.5% | 0.00% | 0.0% |
| Q1 2023 | $2,099 | -25.9% | 54,871 | +6.1% | 0.00% | -25.0% |
| Q4 2022 | $2,834 | -99.8% | 51,713 | +22.4% | 0.00% | +100.0% |
| Q3 2022 | $1,439,000 | +284.8% | 42,261 | +6.8% | 0.00% | +100.0% |
| Q2 2022 | $374,000 | -0.3% | 39,586 | +49.8% | 0.00% | – |
| Q1 2022 | $375,000 | -30.9% | 26,420 | +3.0% | 0.00% | -100.0% |
| Q4 2021 | $543,000 | -7.3% | 25,655 | -2.1% | 0.00% | 0.0% |
| Q3 2021 | $586,000 | -5.6% | 26,201 | +4.7% | 0.00% | 0.0% |
| Q2 2021 | $621,000 | +56.8% | 25,026 | +83.3% | 0.00% | 0.0% |
| Q1 2021 | $396,000 | +6.5% | 13,650 | -5.2% | 0.00% | 0.0% |
| Q4 2020 | $372,000 | -7.9% | 14,400 | +9.7% | 0.00% | 0.0% |
| Q3 2020 | $404,000 | +41.8% | 13,130 | +14.7% | 0.00% | – |
| Q2 2020 | $285,000 | – | 11,446 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $125,180,178 | 50.58% |
| COMMODORE CAPITAL LP | 790,000 | $30,225,400 | 4.60% |
| Redmile Group, LLC | 2,044,389 | $78,218,323 | 3.39% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 202,561 | $7,749,984 | 3.20% |
| Ghost Tree Capital, LLC | 275,000 | $10,522,000 | 3.11% |
| Avidity Partners Management LP | 2,447,000 | $93,622,220 | 3.11% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $22,736,043 | 3.08% |
| Logos Global Management LP | 400,000 | $15,304,000 | 2.19% |
| Yiheng Capital Management, L.P. | 1,125,791 | $43,072,764 | 1.70% |
| Boxer Capital, LLC | 831,495 | $31,813 | 1.56% |